Novartis AG $NVS Shares Sold by BXM Wealth LLC

BXM Wealth LLC reduced its position in Novartis AG (NYSE:NVS) by 88.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,840 shares of the company’s stock after selling 37,977 shares during the quarter. BXM Wealth LLC’s holdings in Novartis were worth $739,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after buying an additional 2,666 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Novartis by 102.8% in the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after acquiring an additional 11,444 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Novartis in the 1st quarter valued at approximately $1,764,000. Sivia Capital Partners LLC raised its position in shares of Novartis by 48.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares in the last quarter. Finally, Schnieders Capital Management LLC. acquired a new stake in shares of Novartis during the 2nd quarter valued at approximately $202,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Price Performance

Shares of NVS opened at $157.56 on Tuesday. The company has a market cap of $300.66 billion, a P/E ratio of 22.57, a PEG ratio of 2.74 and a beta of 0.46. The stock has a fifty day moving average price of $149.20 and a 200 day moving average price of $149.83. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.11 by ($0.12). The company had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.Novartis’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business earned $2.28 earnings per share. On average, research analysts forecast that Novartis AG will post 8.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NVS has been the subject of a number of research reports. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Morgan Stanley increased their target price on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Argus upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Wednesday, March 11th. Finally, Sanford C. Bernstein raised shares of Novartis to a “hold” rating in a report on Thursday, March 19th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Novartis presently has an average rating of “Hold” and an average price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.